Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer

Role of p53 in transcriptional repression of SVCT2

(2021) Eun Ho Kim et al.   MOLECULAR BIOLOGY REPORTS

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer

(2021) Lixia Cao et al.   Frontiers in Oncology

Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer

(2021) Yanchun Meng et al.   Annals of Palliative Medicine

Exportin 1 inhibition as antiviral therapy

(2020) Md. Hafiz Uddin et al.   DRUG DISCOVERY TODAY

Breast cancer: Biology, biomarkers, and treatments

(2020) Khadijeh Barzaman et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

(2020) Terence C. S. Ho et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers

(2020) Eylem Kulkoyluoglu Cotul et al.   Cancers

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

(2019) Maria Mrakovcic et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

(2019) Michael Shafique et al.   ONCOLOGIST

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Zefei Jiang et al.   LANCET ONCOLOGY

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications

(2018) Pingping Guo et al.   PATHOLOGY & ONCOLOGY RESEARCH

Nuclear Export Inhibition for Pancreatic Cancer Therapy

(2018) Irfana Muqbil et al.   Cancers

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

(2017) Yuankai Shi et al.   Journal of Hematology & Oncology

CRM1 Inhibitors for Antiviral Therapy

(2017) Cynthia Mathew et al.   Frontiers in Microbiology

Targeting Cancer at the Nuclear Pore

(2016) Asfar S. Azmi et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

(2015) F. Conforti et al.   CLINICAL CANCER RESEARCH

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

(2014) Kaushal Parikh et al.   Journal of Hematology & Oncology

Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy

(2014) D. S. P. Tan et al.   Cancer Discovery

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

(2013) Yushi Yao et al.   PLoS One

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

(2012) Li Shen et al.   OncoImmunology

The impact of acetylation and deacetylation on the p53 pathway

(2011) Christopher L. Brooks et al.   Protein & Cell

Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase

(2008) G. S. Jones et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY